Clinical Trials

In preclinical and clinical trials, VT-122 has exhibited a wide range of anti-tumor and immune modulatory activity, alone or in combination with other therapies.

The following two studies are underway.

Title: Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)

http://clinicaltrials.gov/show/NCT01265576

Title: Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

http://clinicaltrials.gov/show/NCT01857817

The following study is complete.

Title: Regimen for the Treatment of Cachexia in Subjects With NSCLC (VT-122)

http://clinicaltrials.gov/show/NCT00527319